Drug Development
Deal signed for preclinical candidates for metabolic syndrome, cancer
Published in Health and Medicine Week, July 18th, 2005
The two compounds are designated BL-2030, a soluble receptor that targets cancer cells that will be developed first for the treatment of prostate cancer, and BL-2040, a small molecule for the treatment of hypertension, obesity, and metabolic syndrome.
The worldwide exclusive license for the development of BL-2030 was signed with BioRap Technologies, a private company established to manage the commercialization of intellectual property developed by members of the Rappaport Family Institute for Research in the Medical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
More Articles from Health and Medicine Week
- Attention Deficit Hyperactivity Disorder
Referral bias underlies putative gender differences in symptoms - Cosmetics
OTC progesterone cream results in significant drug exposure - Headache and Migraine
Almotriptan effective in patients with poor response to sumatriptan - Infection Control
Guidance on public reporting of healthcare-related infections released - MMR Vaccine
Eliminating MMR immunizations does not decrease autism incidence - AIDS-Related Kaposi Sarcoma
Docetaxel rapidly effective in anthracycline-pretreated AIDS-related KS patients - More from this issue of Health and Medicine Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
